Patients with liver cirrhosis and first-time hydropic decompensation
Study objective:
To analyze whether early TIPS placement directly at first hydropic decompensation leads to improved transplant-free survival compared to standard therapy, Further information can be found here.
Contact person:
Prof. Dr. Dominik Bettinger
Liver-HERO
Target group:
Patients with hepatorenal syndrome in liver cirrhosis
Study objective:
Efficacy of TIPS (transjugular intrahepatic portosystemic shunt) compared to standard therapy
Contact person:
Prof. Dr. Dominik Bettinger
STOPPIT study
Target group:
Inpatients (or recently hospitalized) with liver cirrhosis and currently taking proton pump inhibitors = PPI ("gastric protection" - e.g. omeprazole, pantoprazole).
Study objective:
Effect of discontinuation of PPI on the course of the disease.
Contact person:
Prof. Dr. Dominik Bettinger
NUT-22
Target group:
Patients with primary sclerosing cholangitis (PSC) who have previously participated in the NUC-5 study
Study objective:
To evaluate the safety, tolerability and efficacy of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC).
Contact person:
Prof. Dr. Tobias Böttler
BIO89-100-131 Medpace
Target group:
Patients with metabolic-associated steatohepatitis (MASH) and fibrosis
Study objective:
Evaluation of the effect and safety of pegozafermin compared to a placebo preparation in patients with MASH and fibrosis
Contact person:
Prof. Dr. Tobias Böttler
BIO89-100-132 Medpace
Target group:
Patients with compensated cirrhosis due to metabolic-associated steatohepatitis (MASH)
Study objective:
Evaluation of the effect and safety of pegozafermin compared to a placebo preparation in patients with compensated cirrhosis due to MASH
Contact person:
Prof. Dr. Tobias Böttler
ABC HCC
Target group:
Known hepatocellular carcinoma
Study objective:
To evaluate the efficacy of atezolizumab in combination with bevacizumab compared to transarterial chemoembolization (TACE) in patients with intermediate stage liver cancer.
Contact person:
PD Dr. Michael Schultheiß, Prof. Dr. Bertram Bengsch
